Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and wearables join forces to fight muscle loss in seniors

NCT ID NCT07426159

Knowledge-focused Sponsor: Tel Aviv University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to improve how we detect and treat sarcopenia—age-related muscle loss that can lead to frailty and disability. Researchers will use artificial intelligence to analyze data from body scans, strength tests, and wearable sensors to identify people at risk early. Then, 120 adults aged 50-70 will receive a personalized 12-week exercise and nutrition plan guided by AI. The goal is to prevent muscle decline and keep older adults stronger and healthier.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 50-70 years * At risk for sarcopenia based on muscle mass and/or muscle function screening * Able to participate in supervised exercise training * Willing to comply with study procedures and provide written informed consent Exclusion Criteria: * Participation in structured exercise or weight loss programs within the past 6 months * Unstable body weight (\>±5%) in the past 6 months * Current smoking or smoking within the past 6 months * Pregnancy, breastfeeding, or post-menopause * Contraindications to MRI (e.g., implanted devices, tattoos, permanent makeup) * Severe cardiopulmonary disease (e.g., recent myocardial infarction, unstable angina) * Musculoskeletal or neuromuscular conditions limiting exercise participation * Cognitive impairment * Chronic diseases including cancer, diabetes, thyroid disease, hypertension, or chronic renal failure * Use of medications affecting metabolism * Secondary liver disease (viral, autoimmune, alcoholic, or drug-induced) * Alcohol intake \>20 g/day (women) or \>30 g/day (men)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related muscle loss are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related muscle loss Sarcopenia

Contacts and locations

Locations

  • Sylvan Adams Sport Institute

    Tel Aviv, 69978, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.